Prosensa Holding, a biotechnology and life sciences firm from the Netherlands, initiated its first trading day on the Nasdaq New York. The company is a member of Indivest's portfolio of companies.

Prosensa is the second company from Idinvest to complete a market listing this year. Early this year, French therapeutic company Erytech Pharma was also included in the list of the New York Stock Exchange Euronext Paris. Erytech Pharma specializes on therapeutic treatment of cancer.

The initial public offering was announced on June 27. The price of the IPO was $13 for each of the 6 million shares being offered. This corresponds to a total of $442 million worth of company market capital.

Prosensa develops RNA modulating therapeutics used the treatment of genetic disorders. The current focus of the company is on rare neurological diseases that are classified as degenerative.  Diseases under this category include muscular dystrophy, myotonic dystrophy, and Huntington's disease.